Health breakthroughs and money matters, in plain words

Home » Amgen and AstraZeneca Combination Therapy Shows Unprecedented Survival Gains in Lung Cancer

Imdelltra Plus Imfinzi Cuts Risk of Death 58% in Small Cell Lung Cancer Trial

By

–

Amgen and AstraZeneca Combination Therapy Shows Unprecedented Survival Gains in Lung Cancer

Small cell lung cancer is one of the hardest cancers to hold back, and for families facing it, months matter. A Phase 3 trial now suggests that adding Amgen’s Imdelltra (tarlatamab-dlle) to AstraZeneca’s Imfinzi (durvalumab) can buy a good deal more of them. Amgen says the combination cut the risk of death by 58% as a first-line maintenance treatment for extensive-stage disease.

What the trial found

The DeLLphi-305 results were presented at the 2026 European Society for Medical Oncology Congress in a Presidential Symposium and published at the same time in The New England Journal of Medicine. The trial enrolled 563 patients whose cancer had not progressed after initial treatment with durvalumab, platinum-based chemotherapy and etoposide. Half received Imdelltra plus Imfinzi and half received Imfinzi alone.

Median overall survival was 21.1 months with the combination and 12.7 months with Imfinzi alone. Nearly 80% of patients on the combination were alive at one year, against 53% on Imfinzi alone. Median progression-free survival more than tripled, from 1.9 months to 7.4 months. Among patients with measurable disease, 26.4% responded to the combination, compared with 4.1% on Imfinzi alone.

Jacob Sands, M.D., of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, said the benefit held across groups, including patients with brain or liver metastases. He also stressed that follow-up is about 16 months, so this is an interim read and the survival figures will mature. The trial is sponsored by Amgen, with partial funding and durvalumab supplied by AstraZeneca.

The side effects

The gains came with a cost. Grade 3 or higher treatment-related adverse events occurred in 20.9% of patients on the combination and 10.8% of those on Imfinzi alone. About half of the Imdelltra patients, 49.6%, developed cytokine release syndrome. Almost all of it was grade 1 or 2, with a single grade 3 case and nothing worse. Immune effector cell-associated neurotoxicity syndrome affected 1.1%. Patients were monitored in a healthcare setting for one to two hours after their first two infusions, longer in some regions including Europe.

What this means for patients

Imdelltra works by binding to DLL3, a protein found on the surface of small cell lung cancer cells in roughly 85% to 96% of patients but rarely on healthy cells, and to CD3 on T cells, which draws the immune system to the tumor. Jay Bradner, M.D., Amgen’s head of research and development, called the results “an unprecedented advance” and said the company is moving quickly to share them with regulators worldwide. Andrea Ferris of the LUNGevity Foundation said patients have had “too few treatment advances and too little time”, and described the results as hope for “more life milestones, more moments of joy”.

Anyone with this diagnosis should talk to their oncologist about whether and when this approach might apply. Imdelltra is currently approved only for patients whose disease has progressed on or after platinum-based chemotherapy. Chief Medical Officer Paul Burton told Fierce Pharma the current label covers about 13,000 U.S. patients, a number that could reach 35,000 to 40,000 if Amgen’s other earlier-line trials succeed.

Sources

Photo: FDV (CC BY-SA 4.0)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News